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Abstract
Background: Severe malaria is a medical emergency associated with high mortality. Adequate treatment requires
initial parenteral therapy for fast parasite clearance followed by longer acting oral antimalarial drugs for cure and
prevention of recrudescence.
Methods: In a randomized controlled clinical trial, we evaluated the 42-day parasitological outcomes of severe
malaria treatment with intravenous artesunate (AS) or intravenous quinine (QNN) followed by oral artemisinin based
combination therapy (ACT) in children living in a high malaria transmission setting in Eastern Uganda.
Results: We enrolled 300 participants and all were included in the intention to treat analysis. Baseline characteristics
were similar across treatment arms. The median and interquartile range for number of days from baseline to
parasite clearance was significantly lower among participants who received intravenous AS (2 (1–2) vs 3 (2–3), P < 0.
001). Overall, 63.3% (178/281) of the participants had unadjusted parasitological treatment failure over the 42-day
follow-up period. Molecular genotyping to distinguish re-infection from recrudescence was performed in a sample
of 127 of the 178 participants, of whom majority 93 (73.2%) had re-infection and 34 (26.8%) had recrudescence. The
42 day risk of recrudescence did not differ with ACT administered. Adverse events were of mild to moderate
severity and consistent with malaria symptoms.
Conclusion: In this high transmission setting, we observed adequate initial treatment outcomes followed by very
high rates of malaria re-infection post severe malaria treatment. The impact of recurrent antimalarial treatment on
the long term efficacy of antimalarial regimens needs to be investigated and surveillance mechanisms for resistance
markers established since recurrent malaria infections are likely to be exposed to sub-therapeutic drug
concentrations. More strategies for prevention of recurrent malaria infections in the most at risk populations are
needed.
Trial registration: The study was registered with the Pan African Clinical Trial Registry (PACTR201110000321348).
Keywords: Artesunate, Quinine, Artemisinin combination therapy, Severe malaria, Re-infection
* Correspondence: pbyakika@gmail.com
1Department of Medicine, College of Health Sciences, Makerere University, P. O.
Box, 7072 Kampala, Uganda
2Infectious Diseases Institute, Kampala, Uganda
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Byakika-Kibwika et al. BMC Infectious Diseases  (2017) 17:794 
DOI 10.1186/s12879-017-2924-5
Background
Malaria is a major cause of morbidity and mortality
worldwide. In 2015, the WHO estimates that there were
214 million cases of malaria and 438,000 deaths world-
wide, with 90% of deaths occurring in Africa [1]. The
vast majority of severe malaria cases and deaths occur
among children younger than 5 years of age and are
caused by Plasmodium falciparum [2]. Severe malaria is
a life threatening emergency, which usually causes death
in the first 24–48 h following hospitalization. Mortality
reduces from almost 100% to 10–20% following prompt
and effective treatment [2]. The primary objective of se-
vere malaria treatment is to prevent death while second-
ary objectives include prevention of disability and
recrudescence. Treatment includes initial parenteral
therapy for fast parasite clearance for a minimum of
24 h and when the patient is able to tolerate oral ther-
apy, an effective oral artemisinin based combination
therapy (ACT) is administered to achieve complete para-
site clearance and to prevent recrudescence.
Two previous multicentre randomized trials demon-
strated superiority of intravenous artesunate (AS) over
intravenous quinine (QNN) for treatment of severe mal-
aria in Africa and Asia [3–7]. Intravenous AS was associ-
ated with significant reduction in mortality of 22.5% in
African children and 38.6% in Asian children and adults.
These data led to the recommendation by the World
Health Organization (WHO) for intravenous AS to re-
place intravenous QNN as the treatment of choice for
severe P. falciparum malaria worldwide. Uganda adopted
the policy to use intravenous AS in 2013 with intraven-
ous QNN recommended as an alternative. To date,
intravenous QNN is still widely prescribed due to incon-
sistent availability and frequent stock-outs of intravenous
AS in health facilities [8].
The Ugandan malaria treatment policy recommends
artemether-lumefantrine (AL) and dihydroartemisinin-
piperaquine (DP) as the first and second line ACTs
for follow-on therapy. Previous studies demonstrated
excellent efficacy and effectiveness of both AL and
DP for treatment of uncomplicated malaria [9–11]
with the additional advantage of post treatment
prophylactic effect of up to 28 days for AL and
35 days for DP [12]. Data on the parasitological out-
comes following treatment of severe malaria with par-
enteral antimalarial drugs followed by oral ACTs are
limited. Patients with severe malaria may survive
death with the initial parenteral antimalarial regimen
but may suffer morbidity due to recurrent parasit-
aemia [13] from reinfection and recrudescence. We
evaluated the 42-day parasitological treatment out-
comes and safety of ACT (AL or DP) following treat-
ment of severe malaria among patients attending
Tororo District Hospital in Eastern Uganda.
Methods
Study design, site and population
The study was a randomized single blind clinical trial
conducted in Tororo District Hospital situated in East-
ern Uganda, an area with perennial malaria transmission
and an annual entomological inoculation rate estimated
to be 310 infective bites per person per year [14].
Consecutive patients presenting to the hospital with
symptoms and signs of severe malaria and a microscopy
positive thick blood film for malaria parasites were re-
ferred to the study physicians for further assessment for
study eligibility. Patients were enrolled if they fulfilled
the following inclusion criteria: age 6 months and above,
with history of fever in the last 24 h or axillary
temperature > 37.5 °C, a diagnosis of severe malaria and
whose parent or guardian provided written informed
consent. Severe malaria was defined as presence or his-
tory of fever plus a positive blood film for P.falciparum
malaria with at least one of the following symptoms and
signs; repeated convulsions (more than 2 in 24 h), im-
paired consciousness (Glasgow Coma Score < 11 for
adults and Blantyre Coma Score < 3 for children), coma,
hyperpyrexia (axillary temperature >/= 40 °C), respira-
tory distress (acidotic breathing), inability to tolerate oral
therapy and vomiting all oral intake, circulatory collapse
or shock (systolic Blood Pressure < 80 mmHg in adults
and <50 mmHg in children), spontaneous bleeding,
haemoglobinuria (tea colored urine), jaundice, prostra-
tion (extreme weakness with inability to sit, stand or
walk without assistance), severe normocytic anemia
(hemoglobin <5 g/dL), hypoglycemia (blood sugar
<2.2 mmol/l or 40 mg/dL), renal impairment (serum
creatinine >265 μmol/l), and hyperparasitaemia (>10%).
Patients were excluded if they had obvious concomitant
febrile illness, history of allergy to any of the study
drugs, were resident more than 20 km from the hospital
and therefore could not return for follow-up visits or if
they had history of receipt of an effective antimalarial
drug within 72 hours before presenting to hospital. The
last exclusion criterion was modified to exclude patients
with history of receipt of an effective antimalarial drug
within 24 hours before presenting to hospital due to
large numbers of patients reporting self medication with
antimalarial drugs prior to presenting to the hospital,
thus affecting recruitment.
Study procedures
Randomization
A 2-stage block randomization procedure was per-
formed by an independent statistician using the R com-
puter software in blocks of 20. Participants were first
randomized to intravenous AS or intravenous QNN then
to AL or DP. Computer-generated randomization codes
were enclosed in sequentially numbered opaque sealed
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envelopes containing treatment allocation. After meeting
study eligibility criteria, the study nurse assigned the
next envelope to the participant, opened the envelope
and assigned treatment allocation. Treatment was imme-
diately initiated.
Treatment
Intravenous AS (Guilin Pharmaceutical Factory, Guangxi,
China) was administered as 2.4 mg/kg at start of treatment,
repeated at 12 and 24 h and every 24 h till the switch to
oral therapy. Each 60 mg vial of artesunic acid was dis-
solved in 1 mL of 5% sodium bicarbonate (provided in the
pack) and mixed with 5 mL of 5% dextrose, then injected
as a slow bolus into an indwelling intravenous cannula.
Intravenous QNN dihydrochloride (Rotex, Trittau,
Germany) was administered as 10 mg/kg body weight in
5% dextrose (10 ml/kg) through an indwelling catheter over
4 h and repeated 8 hourly till the switch to oral therapy.
Intravenous antimalarial therapy was administered for
a minimum of 24 h and when participants could tolerate
oral therapy, they were given a full course of the oral
ACT assigned. Oral AL (Coartem, Novartis, 20 mg arte-
mether/120 mg lumefantrine tablets) was administered
according to body weight as; one (5–14 kg), two (15–
24 kg), three (25–34 kg) and four (>35 kg) tablets given
twice daily for 3 days. Parents and care takers were given
instructions to administer the second dose of AL 8
hours after the first then every morning and evening to
complete a 3 day course and all doses to be administered
after food or a cup of milk. Oral DP (Eurartesim, Sigma-
Tau, dihydroartemisinin (DHA) 40 mg + piperaquine
(PQP) 320 mg tablets) was administered targeting a total
of 6.4 and 51.2 mg/kg of dihydroartemisinin and pipera-
quine, respectively, given in three equally divided doses
to the nearest quarter tablet. We used a pill cutter to en-
sure that the tablet fractions were as close to the nearest
quarter tablet as possible.
All participants received paracetamol in a dose of
15 mg/kg at 8 hourly intervals. Adjunctive and support-
ive treatment such as diazepam for convulsions and dex-
trose for hypoglycemia was given in accordance with the
Uganda Ministry of Health guidelines. All caretakers
were given counseling on adherence to drugs, follow-up
visits and potential drug side effects by the study nurse.
They were instructed to observe the participants for
30 min after drug administration and if vomiting oc-
curred they were to administer another dose. If vomiting
occurred repeatedly (> 3 times) they were to bring back
the participant to the study clinic for evaluation and
treatment plus collection of additional doses of drugs.
Follow-up
Serial blood smears were performed at 0, 1, 2, 4, 6, 8, 10,
12, 16, 20, 24 h post start of intravenous drugs followed
by every 6 h until 6 h after parasite clearance. Partici-
pants were discharged from hospital when the blood
smear was negative for malaria parasites and were
followed up for 42 days to ascertain parasitological out-
comes and monitor for adverse events. They were
brought back to the clinic for follow up assessment on
days 1, 3, 7, 14, 21, 28, 35, 42 post the commencement
of ACT administration, and any unscheduled day if the
participant felt unwell. Follow-up assessment on each of
these days consisted of medical history, physical examin-
ation and a finger prick to collect blood on slides for
thick blood film for malaria diagnosis and on filter paper
for genotyping. Participants with positive malaria films
were reassessed for severity and treated accordingly. Par-
ticipants who returned with severe malaria were re-
admitted and treated with intravenous AS plus AL.
Those who returned with uncomplicated malaria were
evaluated for treatment failure and treated according to
national guidelines with DP if the blood smear was posi-
tive before day 14 and AL if it was positive after day 14
post commencement of ACT. Participants were discon-
tinued from study follow up if they could not continue
with the prescribed medication, missed a scheduled
follow-up visit and could not be located at home or if
they administered additional antimalarial drugs outside
the study protocol.
Laboratory procedures
Thin smears were performed to determine the type of
malaria parasite species and thick smears to determine
the parasite density and for detection of parasitemia dur-
ing follow-up. Thick blood smears were stained using
3% Giemsa for 30 min and read by experienced labora-
tory technologists. All slides were read by two independ-
ent microscopists and any discrepant results were
reviewed by a tie breaker. Microscopists were blinded to
participants’ treatment assignment. In order to blind the
microscopists, blood samples were drawn by the study
nurse and study numbers were used to label all samples.
The study numbers were not known by the microsco-
pists and they did not have access to study data includ-
ing study databases, participants’ assessments and
clinical notes. The study doctors and nurses were aware
that laboratory technicians were blinded to treatment as-
signment and were trained not to reveal the treatment
assignments to the microscopists.
Parasite density was calculated by counting the num-
ber of asexual parasites (ring stages) per 200 white blood
cells (WBCs) or per 500 if the count was less than ten
parasites per 200 WBCs, assuming a WBC count of
8000/uL of blood. A smear was considered negative if
no parasites were seen after review of 100 high-power
fields. Complete blood count and hemoglobin estimation
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were performed using the Coulter counter, Beckman
coulter, Life Science, United States of America.
Filter paper blood samples were collected and subse-
quently molecular genotyping was conducted for partici-
pants with parasitological treatment failure to distinguish
re-infection from recrudescence. We used Whatman
3MM Filter paper from Sigma. Molecular genotyping was
performed at the Makerere University-University of Cali-
fornia San Francisco Molecular Biology laboratory in
Mulago, Kampala. Parasite DNA was extracted from filter
paper blood samples collected on the day of enrollment
and the day of parasitological treatment failure using Che-
lex 100 Resin extraction (Bio-Rad Laboratories, Hercules,
CA) as previously described [15]. Paired samples were ge-
notyped. The surface antigen loci MSP1, MSP2 and
GLURP were amplified using previously described primers
[16]. Briefly, 2 μL of template DNA was amplified using
nested polymerase chain reaction (PCR), with second
round primers specific to allelic families: K1, MAD20, and
RO33 for msp1, msp2 and the repeat region of glurp [17].
PCR products were stained with ethidium bromide sepa-
rated by electrophoresis on a 2.5% agarose gel (UltraPure
Agarose; Invitrogen, Carlsbad, CA). GelCompar II soft-
ware (Applied Maths, Sint-Martens-Latem, Belgium) was
used to select alleles and estimate the size of PCR prod-
ucts using a standardized approach [18]. Recrudescence
was defined as the presence of all matched alleles on day 0
and the day of failure at every locus and reinfection de-
fined as at least one locus showing unmatched alleles.
Classification of outcomes
To evaluate the 42 day parasitological treatment out-
comes following treatment of severe malaria with intra-
venous AS or intravenous QNN plus ACT (AL or DP);
we selected the primary study outcome as parasitological
treatment failure unadjusted by genotyping classified as
parasitemia detected by thick blood smear during
follow-up. This primary outcome was selected because it
best represents the treatment outcome measure used in
routine clinical care. The secondary outcomes were
parasitological treatment failure adjusted by genotyping
classified as positive PCR on any follow-up day cate-
gorised as reinfection or recrudescence. Adverse events
were defined as any medical occurrence post study drug
administration. They were graded as mild, moderate, se-
vere and life threatening and their relationship to the
study drug was classified as unrelated, possibly, probably
or definitely related to study drug.
Sample size estimation
We estimated the proportion of parasitological failure of
23.6% for intravenous QNN followed by ACT. Assuming
a 50% difference in the proportion of patients with para-
sites at 24 h following start of IV AS, using an alpha of
5%, power of 80%, and adjusting for possible loss to fol-
low up of 10%, a total of 330 patients were needed.
Statistical analysis
Data were entered and verified using MS ACCESS and
analyzed using STATA version 13.1 (STATA Corpor-
ation, College Station, TX, USA). Descriptive statistics
were used to compare demographic and clinical charac-
teristics among the four study arms. Continuous vari-
ables were compared using Wilcoxon test for non-
normally distributed data. Categorical variables were
compared using Chi-square test. Parasite density was
normalized using logarithmic transformation. Intention-
to-Treat analysis was used, which included all enrolled
participants. Unadjusted treatment failure was classified
as a positive blood smear on any of the follow-up days.
Adjusted treatment failure was classified as either re-
infection or recrudescence based on genotyping. The
risk of treatment failure at 28, 35 and 42 days of follow
up (unadjusted and adjusted by genotyping) were esti-
mated using the Kaplan-Meier survival method and
compared using the Log Rank test. Time at risk was cal-
culated from day one of ACT allocation to date of treat-
ment failure among participants who failed, last day of
follow-up for those who did not complete follow-up, or
day 42 for the patients who completed 42 days of
follow-up. In the analysis for adjusted parasitological
outcomes, only recrudescence was considered as true
parasitological treatment failure. Safety data from all
participants were analyzed. In a sensitivity analysis, we
imputed missing genotype data among the treatment
failures using multiple imputation with chained equa-
tions. Variables included in the imputation model were
age, sex, weight, parasite density at baseline visit and
treatment arm. Five rounds of imputations were per-
formed. Statistical tests were performed at 5% level of
significance and 95% confidence intervals.
Results
We enrolled and followed up 300 participants between
January 2012 and March 2013 (Fig. 1). Baseline charac-
teristics were similar across the four treatment arms
(Table 1). Nineteen participants (6.3%) did not complete
follow-up, of whom; 8 (2.6%) were lost to follow-up, 3
(1%) had protocol violation, 6 (2%) took non study anti-
malarial drugs and were withdrawn and 2 (0.6%) died on
arrival after randomization but before receiving treat-
ment. All the 300 participants were included in the
intention to treat analysis. Follow-up outcomes were
available for 281 (93.7%) of the 300 participants enrolled,
of whom 178 (63.3%) had unadjusted parasitological fail-
ure. One participant developed convulsions within 2 h
of receipt of the first dose of intravenous AS and died.
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Unadjusted parasitological treatment outcomes
The median and interquartile range (IQR) for number of
days to parasite clearance was significantly lower among
participants who received intravenous AS compared with
participants who received intravenous QNN (2 (1–2) vs 3
(2–3), P < 0.001). During the 42-day follow-up period,
63.3% (178/281) of the participants were classified as having
unadjusted parasitological treatment failure; occurring in
41/71 (57.7%, CI 45.4–69.3) of participants who received
AS +AL, 53/79 (67.1%, CI 55.6–77.2) of those who received
AS +DP, 39/79 (49.4%, CI 37.9–60.8) of those who received
QNN+AL and 45/71 (63.4%, CI 51.1–74.5) of those who
received QNN+DP. The 42 day risk of unadjusted para-
sitological treatment failure was 40% lower for participants
who received QNN+AL (HR 0.6, 95% CI 0.39–0.9, p =
0.014) but not different for those who received QNN+DP
(HR 0.8, 95% CI 0.5–1.3, p = 0.55) or AS +AL (HR 0.7, 95%
CI 0.5–1.1, p = 0.16) compared to those who received AS +
DP. The risk of getting unadjusted treatment failure was
not different across the four study arms (p = 0.044) (Fig. 2).
Adjusted parasitological outcomes
Molecular genotyping was performed for the first 127
(71.3%) of the 178 participants with unadjusted
parasitological failures, of whom; 30/127 (23.6%) received
AS + AL, 37/127 (29.1%) received AS +DP, 29/127 (22.8%)
received QNN+AL, and 31/127 (24.4%) received QNN+
DP. Majority (93, 73.2%) had re-infection while 34 (26.7%)
had recrudescence as the cause of treatment failure.
Reinfection occurred in 24/71 (33.8%, CI 23.0–46.0) of
participants who received AS + AL, 30/79 (37.9%, CI
27.3–49.6) of those who received AS +DP, 21/79 (26.6%,
CI 17.3–37.7) of those who received QNN +AL and 18/
71 (25.3%, CI 15.8–37.1) of those who received QNN +
DP. The risk of getting reinfection was not different
across the four study arms (p = 0.155).
Recrudescence occurred in 6/71 (8.4%, CI 3.2–17.5) of
participants who received AS +AL, 7/79 (8.9%, CI 3.6–
17.4) of those who received AS +DP, 8/79 (10.1%, CI 4.5–
18.9) of those who received QNN+AL and 13/71 (18.3%,
CI 10.1–29.3) of those who received QNN+DP. The prob-
ability of having recrudescence was highest among patients
who received QNN+DP (HR 1.95, 95% CI: 0.78–4.89, p =
0.154), followed by QNN+AL (HR 0.95, 95% CI: 0.3–2.6,
p = 0.93) and AS+AL (HR 0.84, 95% CI: 0.28–2.51, p =
0.762) compared to those who received AS +DP. The
42 day risk of recrudescence was not different among the
four ACT study arms (p = 0.055) (Fig. 3).
Fig. 1 Schematic Diagram of the Trial Profile
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In the sensitivity analysis, 41/178 (23.0%) received AS +
AL, 53/178 (29.8%) received AS +DP, 39/178 (21.9%) re-
ceived QNN+AL, and 45/178 (25.3%) received QNN+
DP. Majority (124, 69.7%) had re-infection while 54
(30.3%) had recrudescence as the cause of treatment fail-
ure. Reinfection occurred in 35/71 (49.3%, CI 37.2–61.4)
of participants who received AS + AL, 41/79 (51.9%, CI
40.4–63.3) of those who received AS +DP, 26/79 (32.9%,
CI 22.7–44.3) of those who received QNN+AL and 22/
71 (31.0%, CI 20.5–43.1) of those who received QNN+
DP. The risk of getting reinfection was not different across
the four study arms (p = 0.155). Recrudescence occurred
in 6/71 (8.4%, CI 3.2–17.5) of participants who received
AS + AL, 12/79 (15.2%, CI 8.1–25.0) of those who received
AS +DP, 13/79 (16.4%, CI 9.1–26.5) of those who received
QNN+AL and 23/71 (21.8%, CI 21.8–44.5) of those who
received QNN+DP. The risk of getting recrudescence
was not different across the four study arms (p = 0.055).
Table 1 Baseline characteristics of study participants
Characteristic AS + DP
N = 79
AS + AL
N = 71
QNN + DP
N = 71
QNN + AL
N = 79
Female (%) 36 (45.6) 36 (50.7) 24 (33.8) 37 (46.8)
Age in monthsa 17 (11–26) 16 (10–26) 17 (13–26) 18 (13–26)
Weight (kgs)a 9.5 (8–11.5) 9 (8.1–11) 9.8 (8.8–11) 9.2 (8.4–11)
Temperature (degrees Centigrade)a 38.8 (37.7–39.5) 39.1 (37.7–39.5) 39.1 (37.3–39.5) 38.6 (37.5–39.6)
Parasite density per uL, log10 copiesa 4.82 (4.29–5.10) 4.79 (4.38–5.02) 4.72 (4.19–5.00) 4.73 (4.17–5.03)
Complications at admission, n (%)
Hemoglobin (mg/dL)a 9.1 (7.9–10.5) 9.2 (8.4–10.6) 9.3 (8.4–10.4) 9.4 (8.0–10.3)
Total white blood cell count (a103/uL)a 9.6 (6.9–13.2) 9.2 (7.5–12.3) 9.4 (7.7–12.1) 10.0 (7.0–14.3)
Random blood sugar (mmol/L)a 7.3 (6.3–8.3) 6.8 (6.4–8.3) 6.8 (5.7–8.3) 7.4 (6.25–8.25)
History of repeated convulsions n (%) 6 (7.6%) 3 (4.2%) 8 (11.3%) 1 (1.3%)
History of inability to feed 26 (33.0%) 24 (34.0%) 22 (31.0%) 29 (36.7%)
Prostration (extreme weakness) 22 (27.9%) 15 (21.13%) 21 (29.58%) 21 (26.58%)
Hemoglobinuria 0 0 2 (2.8%) 0
Jaundice 2 (2.5%) 0 3 (4.2%) 3 (3.8%)
Severe anemia 0 0 1 (3%) 2 (2.5%)
Respiratory distress 2 (2.5%) 6 (8.5%) 3 (4.2%) 5 (6.3%)
Impaired consciousness 0 0 1 (1.4%) 0
Abnormal bleeding 2 (2.5%) 1 (1.4%) 0 1 (1.3%)
Hypoglycemia 0 0 0 1 (1.3%)
aValues are presented as medians (IQR)
Fig. 2 Kaplan-Meier survival curves of the risk of unadjusted
treatment failure categorized by ACT arm over 42 days of follow-up
compared using the Log Rank test
Fig. 3 Kaplan-Meier survival curves of the risk of adjusted treatment
failure categorized by ACT arm over 42 days of follow-up compared
using the Log Rank test
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Secondary outcomes
Adverse events occurred commonly and most were of
mild to moderate severity and consistent with malaria
symptoms. The most common were headache, nausea
and vomiting. Among the 281 participants with
complete follow-up, 22 (7.8%) experienced severe ad-
verse events, all classified as unrelated to study drugs.
Severe adverse events were commonest among partici-
pants who received QNN +AL (10/22, 45.4%) followed
by AS + DP (5/22, 22.7%), QNN +DP (4/22, 18.1%) and
least among those who received AS + AL (3/22, 13.6%).
Pneumonia was the commonest severe adverse event oc-
curring in 12/22 (55%) followed by gastro enteritis in 6
(27%) and severe anemia in 4 (18%). All the adverse
events were treated and resolved completely except for
one participant who experienced repeated convulsions,
after receiving intravenous AS and died within 2 h post
drug administration.
Discussion
We evaluated the 42-day parasitological treatment out-
comes and safety following treatment of children with
severe malaria using intravenous AS or intravenous
QNN plus ACT (AL or DP) in Tororo District Hospital
in Eastern Uganda. Participants who received intraven-
ous AS cleared malaria parasites significantly faster than
those who received intravenous QNN, which is consist-
ent with data from previous large trials [3, 5].
There was low mortality among our study participants.
The risk of death for patients with severe malaria is high
and increases with delayed initiation of treatment and in
presence of multiple complications. Risk of death is also
dependent on the patient’s age, background immunity,
pre-morbid and concomitant diseases. We did not study
time intervals between start of symptoms and presenta-
tion to hospital or receipt of antimalarial drug. Our pre-
vious study demonstrated longer duration of illness
before receiving antimalarial medication among children
presenting to hospital with severe malaria compared to
those who had uncomplicated malaria [19]. It is possible
that the participants who died experienced delay in pres-
entation to hospital for various reasons such as chal-
lenges in transportation and poor health seeking
behavior of the care takers.
Both AL and DP were effective at clearing residual
parasites during the 42-day follow-up period. Majority of
our study participants classified as treatment failure ac-
tually suffered re-infection with malaria parasites during
the 42-day follow-up period, with higher reinfection
rates among participants who received AS + ACT com-
pared to QNN +ACT regimens. Our findings are con-
sistent with previous data from similar high malaria
transmission settings which demonstrated high rates of
re-infection with malaria parasites after initial treatment
[20, 21]. Our finding of the highest re-infection rates
among participants who received AS + DP although not
statistically significant, is surprising and difficult to ex-
plain since piperaquine which is the longer acting part-
ner drug in the DP combination is known to have a long
half-life of about 35 days compared to lumefantrine’s
half-life of 28 days, thus is expected to offer longer post
treatment prophylactic effect [12, 21, 22]. Previous stud-
ies reported lower malaria re-infection rates following
treatment with DP compared to AL [20, 21], our find-
ings are possibly limited by the small study numbers for
that comparison. Recurrent malaria infections have been
associated with higher risk for development of symp-
tomatic malaria disease than recrudescent parasitemia
[21, 23]. The high malaria re-infection rate is particularly
significant in patients who have suffered severe malaria
attacks since re-infection is likely to result into recurrent
attacks of severe malaria with co-morbidity such as an-
aemia and resultant negative health and social-economic
impact. Although we did not evaluate the information
given to patients at discharge; we emphasize the import-
ance of education of patients and caretakers on enhan-
cing malaria prevention.
The high rate of malaria re-infection in our study
population, calls for strengthening of national efforts in
malaria prevention, with particular emphasis on high
malaria transmission settings. Interventions such as long
lasting insecticide treated bed nets, indoor residual
spraying with insecticides, malaria chemoprophylaxis for
high risk groups, are highly effective in reducing malaria
morbidity [24] and have been rolled out in this study
area, however, further sensitization of communities and
behavior change are needed. The malaria vaccine would
seemingly provide a more substantial solution to this
overwhelming burden of malaria. The RTS, S/AS01 mal-
aria vaccine was evaluated in a large phase three trial
and received positive regulatory assessment, however,
due to unresolved uncertainties, the WHO made recom-
mendations for further evaluation of this vaccine to ad-
dress gaps in knowledge before wider country level
introduction [24].
It is important to understand why some children living
in malaria endemic areas are at higher risk for develop-
ment of severe malaria and recurrent malaria attacks
than others living in the same areas. Several hypothesis
for host susceptibility to severe malaria and re-infection
have been suggested and some are under study [19, 25].
These need to be evaluated and addressed. Additional
measures to reduce malaria morbidity include use of
Intermittent Preventive Treatment of malaria in infants
(IPTi) using sulphadoxine-pyrimethamine (SP). This is
recommended for areas with low prevalence of key poly-
morphisms that mediate diminished parasite response to
SP. In Uganda; IPTi with SP is not recommended
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because the prevalence of these polymorphisms is consist-
ently greater that 50% across the country [26]. A study in an
area with intense malaria transmission in Malawi demon-
strated that monthly chemoprophylaxis with AL post treat-
ment for severe malarial anaemia reduced rates of
readmittance to hospital for severe anaemia or malaria [27].
Additional studies on IPT for school children living in such
high malaria transmission settings demonstrated acceptable
protective efficacy against clinical malaria, parasitaemia and
anaemia with use of either DP, SP +AS or Amodiaquine +
AS. Monthly DP provided the best protective efficacy [28].
Further studies to investigate the acceptability, cost effective-
ness and long term safety of these IPT regimens are needed.
We demonstrated low levels of recrudescence among our
study participants with no difference in the 42-day risk of
recrudescence among the four ACT study arms. Among
the few participants in whom recrudescence was demon-
strated; the highest probability of recrudescence was among
participants who received the combination of QNN+DP
followed by QNN+AL, although this finding was not sta-
tistically significant possibly due to the limitation of the
small sample size for this comparison. Our study was also
limited by the genotyping method used which is known to
have low resolution. The long acting drug should ideally
mop up all residual parasites to prevent recrudescence
while also preventing re-infection. It is possible that the
QNN+ACT regimens predisposed participants to higher
rates of recrudescence due to slower initial clearance of
parasite biomass by intravenous QNN compared to intra-
venous AS. This finding supports the current recommenda-
tion to use intravenous AS in preference to intravenous
QNN for initial treatment for severe malaria and calls for
improved availability and accessibility to intravenous AS es-
pecially in the high transmission areas.
The study participants’ clinical characteristics did not dif-
fer among study groups with the commonest forms of se-
vere malaria documented to be; inability to feed and
prostration. Our study participants did not present with
very severe forms of malaria, a finding that is consistent
with data from previous studies which demonstrated lower
risk of very severe forms of malaria among individuals liv-
ing in areas with high malaria transmission most likely due
to development of partial immunity from recurrent malaria
infections early in life [29]. Individuals living in malaria en-
demic regions are frequently exposed to malaria infection
and develop partial immunity which helps to clear parasites
from circulation upon subsequent infection preventing the
development of very severe forms of malaria.
Conclusions
We observed adequate initial treatment outcomes
followed by very high rates of malaria re-infection post
severe malaria treatment with intravenous AS or intra-
venous QNN followed by ACT (AL or DP) in a high
malaria transmission setting. The impact of recurrent
antimalarial treatment on the long term efficacy of anti-
malarial regimens needs to be investigated and surveil-
lance mechanisms for resistance markers established
since recurrent malaria infections are likely to be ex-
posed to sub-therapeutic drug concentrations. More
strategies for prevention of recurrent malaria infections
in the most at risk populations are needed.
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